



**For Immediate Release**

## **MANCHESTER HEART CENTRE IN UNITED KINGDOM OBTAINS VMS™ HEART ANALYSIS SYSTEM**

**\*\*\* First Group to use VMS™ in Managing Adult Heart Patients in Europe \*\*\***

**SEATTLE, WASHINGTON, October 20, 2011** – VentriPoint Diagnostics Ltd. ("VentriPoint") (TSXV:VPT; OTC:VPTDF.PK) is pleased to announce the installation of its VentriPoint Medical System (VMS™) at the Manchester Heart Centre at the Central Manchester University Hospitals NHS Foundation Trust, in Manchester UK. The adult congenital heart disease (ACHD) group will use the VMS™ to study adult patients before and after pulmonary-valve replacement.

"We are pleased to be the first adult hospital in Europe to receive a VMS™ and we look forward to using the system in the routine clinical care of our patients," said Dr. Jaspal S. Dua, Consultant Cardiologist in Adolescent and Adult Congenital Heart Disease and Lead for Advanced Imaging in ACHD at the Manchester Heart Centre. "I believe this product will improve care for those patients who require serial assessment of their right ventricular function. This is especially important in areas where access to MRI is limited. We are also excited to begin work to assess right ventricular function before and after pulmonary valve repair in patients with Tetralogy of Fallot (blue baby syndrome)."

Dr. Vaikom Mahadevan, a Consultant Cardiologist specializing in Adult Congenital Heart Disease at the Manchester Heart Centre, also mentioned, "It will be very useful to use this new tool to assess the right ventricular function in other congenital conditions."

VentriPoint's CEO, Dr. George Adams commented, "Given the usual difficulty in establishing a new technology in hospitals, it is very rewarding to announce eleven centres are now using the VMS™ to assess patients. We will continue to aggressively grow in Europe and North America in centres that can showcase the VMS™ and expand its clinical applications."

The Company has installed eleven VMS™ machines to date (three in Canada and two in Europe for clinical use, and six in the USA for investigational use).

Given the overwhelming level of interest from VentriPoint's presence at cardiology exhibitions, the Company has commenced the assembly of four additional VMS™ machines. The VMS™ installations anticipated through the end of 2011 will be at premier institutions around the world for both clinical use and research projects to continue to expand the clinical uses for the VMS™ technology.

### **About Manchester Heart Centre**

The Manchester Heart Centre (MHC), based at Manchester Royal Infirmary, is a major provider of secondary and Tertiary Cardiac Services to the population of Great Manchester, the Northwest Region and beyond. Last year, the centre undertook over 6,000 echocardiograms and saw just under 5,000 new patients in clinics. Over 4,000 cardiology procedures were undertaken. The centre is staffed by 13 consultant Cardiologists and 6 consultant Cardiac Surgeons. MHC is the only

recognized Supra-Regional Centre for Adult Congenital Heart Disease (ACHD) in the Northwest of England and North Wales. The estimated population of the ACHD patients in the region is in excess of 20,000. Around 50% of these will have moderate to complex congenital heart disease and will require life-long care and management, which will be significantly dependent on advanced imaging. VentriPoint Medical System will greatly help in that regard.

Manchester Royal Infirmary is one of five hospitals run by Central Manchester University Hospitals NHS Foundation Trust. The Trust also includes the Royal Manchester Children's Hospital, Saint Mary's Hospital, Manchester Royal Eye Hospital and University Dental Hospital of Manchester.

### **About VentriPoint Diagnostics Ltd.**

VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. The VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure - a multibillion-dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of VentriPoint's VMS™ diagnostic tool and VentriPoint is pursuing the US-FDA approval through the 510(k) process.

For further information, please contact:

#### **VentriPoint Diagnostics Ltd.**

Dr. George Adams, CEO  
Telephone: (206) 283-0221, ext. 401  
[email: gadams@ventripoint.com](mailto:gadams@ventripoint.com)

#### **Howard Group Inc.**

Peter Weichler/David Burwell  
Telephone: 1.888-221-0915 or 403-221-0915  
email: [Peter@howardgroupinc.com](mailto:Peter@howardgroupinc.com)  
[Dave@howardgroupinc.com](mailto:Dave@howardgroupinc.com)

**FORWARD-LOOKING STATEMENTS:** The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release*